Effectiveness of Extended Release Methylphenidate in Reducing Cannabis Use in Young Cannabis-Dependent Patients with Attention Deficit Hyperactivity Disorder (ADHD)

Effectiveness of Extended Release Methylphenidate in Reducing Cannabis Use in Young Cannabis-Dependent Patients with Attention Deficit Hyperactivity Disorder (ADHD) - METHACAN

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-000386-77-FR

Enrollment

Registered

2018-01-22

Start date

2017-06-13

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 20.1 Level: LLT Classification code 10007177 Term: Cannabis dependence System Organ Class: 100000004873

Interventions

Trade Name: RITALINE L.P. 10 mg, gélule à libération prolongée Product Name: RITALINE L.P. 10 mg, gélule à libération prolongée Pharmaceutical Form: Capsule INN or Proposed INN: Chlorhydrate de méthyl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: 35 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 35 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s): ;Timepoint(s) of evaluation of this end point: 12 weeks	—

Secondary

Measure	Time frame
Timepoint(s) of evaluation of this end point: 4, 8, 12 weeks and 12 months	—

Countries

France

Contacts

Public ContactDRCI Hôpital St Louis

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

elodie.soler@aphp.fr

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026